Advanced Enzyme Technologies Limited has notified stock exchanges regarding the structural conversion of its statutory auditing firm from M S K A & Associates to M S K A & Associates LLP, effective January 13, 2026. The company received formal intimation from the auditors on January 14, 2026, and subsequently informed BSE and NSE on January 15, 2026.

Auditor Firm Conversion Details

The statutory auditing firm M S K A & Associates, Chartered Accountants, has converted itself into a Limited Liability Partnership under the provisions of the Limited Liability Partnership Act, 2008. The firm is now operating as M S K A & Associates LLP, Chartered Accountants with a new ICAI Firm Registration Number 105047W/W101187.

Continuity of Audit Services

The conversion to LLP structure does not impact the ongoing audit engagement with Advanced Enzyme Technologies. The newly formed M S K A & Associates LLP will continue to function and discharge its duties as the statutory auditors of the company for the remaining period of their appointed term. This ensures seamless continuation of auditing services without any disruption to the company's statutory compliance requirements.

Regulatory Communication

Advanced Enzyme Technologies' Company Secretary and Head of Legal, Sanjay Basantani, communicated this development to both major stock exchanges where the company's shares are listed. The notification was sent to BSE Limited (Scrip Code: 540025) and National Stock Exchange of India Limited (Trading Symbol: ADVENZYMES) as part of regulatory disclosure requirements under applicable listing regulations.

The company emphasized that this structural change in the auditing firm is purely administrative and maintains the same professional relationship and audit standards that were previously established with M S K A & Associates.

Advanced Enzyme Technologies , a leading enzyme company, has reported strong financial results for the second quarter of fiscal year 2026, with significant growth across all business segments.

Financial Highlights

• Revenue increased by 26% year-over-year (YoY) to INR 1,845.00 million
• EBITDA rose by 42% YoY to INR 601.00 million, with a margin of 33%
• Profit After Tax (PAT) grew by 34% YoY to INR 447.00 million, with a margin of 24%

Segment-wise Performance

The company's Human Healthcare segment, which includes pharmaceuticals and nutritional products, remains the largest contributor to revenue. The Bioprocessing segment showed particularly strong growth, driven by robust performance in the food business.

Growth Drivers and Challenges

Advanced Enzyme Technologies attributes its growth to several factors:

1. Expansion in Asia and Europe markets
2. Strong performance across all business segments
3. Operational efficiencies and product mix improvements

However, the company faces challenges related to U.S. tariffs, which could impact EBITDA by INR 10.00-11.00 crores. Management is exploring strategies to mitigate these effects.

Future Outlook

Despite the tariff challenges, Advanced Enzyme Technologies maintains its mid-teen growth guidance for the fiscal year. The company is focusing on:

1. Expanding its product portfolio through ongoing R&D efforts
2. Exploring new geographies and market segments
3. Potential acquisitions in areas such as animal feed and probiotics

Management Commentary

Mukund Kabra, Whole Time Director, stated, "We have witnessed growth across all business segments of our presence. We anticipate that our strong growth trajectory will continue across all business segments in the foreseeable future."

The company is also investing in a new R&D center, expected to be partially operational by the end of the current fiscal year, which should further support its growth initiatives.

Advanced Enzyme Technologies' strong performance in Q2 FY26 demonstrates its resilience and ability to capitalize on market opportunities despite global challenges. The company's focus on diversification and innovation positions it well for continued growth in the enzyme market.